Just the Facts: Immuron records 13% sales growth for Travelan

Proactive - Interviews for investors

Proactive’s Tylah Tully breaks down ‘Just the Facts’ of the latest quarterly update from Immuron Ltd (NASDAQ: IMRN, ASX: IMC). The company has recorded strong sales growth for its immune supplement Travelan® during the September quarter. The product, designed to target pathogenic bacteria and toxins in the gastrointestinal tract, generated A$1.5 million in global sales, a 13% increase compared to the previous quarter. In Australia, Travelan® sales reached A$1 million, marking a 3% rise from the June quarter. The company has expanded its domestic distribution, adding placements in nine additional pharmacy banner groups. In North America, sales surged by 48%, rising to A$500,000 from A$300,000 in the previous period. Immuron achieved its highest monthly sales on Amazon in the US and secured distribution across 10 pharmacy and grocery retailers in Canada. Immuron says its achieving strong growth in North America and Australia and plans to build on this momentum as it continues expanding its global distribution network. #ProactiveInvestors #Immuron #ASX #JusttheFacts #Travelan, #SalesGrowth, #AmazonSuccess, #ImmuneHealth, #AustraliaPharmacy, #NorthAmericaExpansion, #HealthSupplements, #ImmuneSupport, #GastrointestinalHealth #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews